T he early initiation of insulin therapy to achieve good metabolic control is being increasingly considered in type 2 diabetes (1), but barriers, including fear of hypoglycemia, need to be overcome to achieve target glycemic control (2) .
Insulin glargine (glargine; Lantus) is a once-daily, basal human insulin analog. The 24-h duration and flat time-action profile of glargine (3) should give flexibility to patients in terms of the injection time despite targeting fasting blood glucose (FBG) close to normal: administration should be possible at any time of day provided it is at the same time each day. Previously, we have demonstrated similar levels of nocturnal hypoglycemia but better glycemic control with morning versus bedtime glargine plus three milligrams glimepiride (4) . , and diabetes duration 9.5 vs. 10.3 years). The primary outcome, incidence of nocturnal hypoglycemia (hypoglycemia while the patient was asleep, after the evening injection and before rising), was compared using one-sided 95% CIs.
RESEARCH DESIGN AND METHODS
RESULTS -The frequency of nocturnal hypoglycemia was equivalent between the groups, with morning glargine noninferior to bedtime (13.0 vs. 14.9%, 95% CI Ϫ100 to 2.84%). Most patients who experienced nocturnal hypoglycemia had only one episode (51.3 vs. 54.8%).
At end point, clinically meaningful reductions in HbA 1c were observed in both groups: Ϫ1.7 Ϯ 1.2%, from 8.8 Ϯ 1.0 to 7.2 Ϯ 1.1% (morning) and Ϫ1.6 Ϯ 1.2%, from 8.8 Ϯ 1.0 to 7.2 Ϯ 1.1% (bedtime). A reduction in FBG also occurred: Ϫ 7 6 . 5 5 Ϯ 5 0 . 7 6 ( m o r n i n g ) v s . Ϫ80.69 Ϯ 49.41 mg/dl (bedtime) (P ϭ 0.08), with no significant differences in hypoglycemia. The proportion of patients with HbA 1c Յ7.0% was comparable for the two treatment groups (P ϭ 0.66), with 48% (n ϭ 149) and 47% (n ϭ 143) of patients achieving HbA 1c Յ 7.0% at end point in the morning and bedtime groups, respectively. Baseline to end point decreases in nocturnal and mean daily blood glucose were similar in both groups (nocturnal blood glucose: Ϫ68.64 Ϯ 58.53 vs. Ϫ70.10 Ϯ 56.72 mg/dl, P ϭ 0.52; mean daily blood glucose: Ϫ73.42 Ϯ 56.55 vs. Ϫ68.35 Ϯ 54.45 mg/dl, P ϭ 0.13; all morning versus bedtime). Mean daily insulin dose at end point was comparable between the groups (34.7 Ϯ 17.4 vs. 32.4 Ϯ 17.0 IU, P ϭ 0.15).
Treatment-emergent adverse events were observed in 308 patients, with no clinically relevant between-treatment differences. Possible treatment-related treatment-emergent adverse events occurred in 3.5% of patients (morning: 2.9%; bedtime: 4.1%); 8.0% experienced severe treatment-emergent adverse events (morning: 8.8%; bedtime: 7.3%).
CONCLUSIONS -In conclusion, glargine, due to its 24-h action and flat profile, is an appropriate and flexible add-on therapy to start insulin treatment in patients with type 2 diabetes. Flexible dosing with simple glimepiride/glargine regimens achieved significant and practically meaningful improvements in glycemic control, regardless of administration time and without differences in hypoglycemia. This flexibility should facilitate initiation of and adherence to insulin therapy and thus lead to improvements in glycemic control. 
